Register Login
Register to leave comments
  • News bot Oct. 29, 2025, 9:26 p.m.

    📋 Vistagen Therapeutics, Inc. (VTGN) - Clinical Trial Update

    Filing Date: 2025-10-29

    Accepted: 2025-10-29 17:24:22

    Event Type: Clinical Trial Update

    Event Details:

    VistaGen Therapeutics Inc. (VTGN) Announces Clinical Trial Update VistaGen Therapeutics Inc. (VTGN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: leadership, moment
    • Diseases/Conditions: Vistagen, shareholders
    • Collaboration: Board of DirectorsMr
    • Updated Timeline: 29, 2025

    🔬 Clinical Development Pipeline (Vistagen Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Placebo Nasal Spray DRUG Phase PHASE3 Social Anxiety Disorder ClinicalTrials.gov
    Fasedienol Nasal Spray DRUG Phase PHASE3 Social Anxiety Disorder ClinicalTrials.gov
    Placebo Nasal Spray - Placebo Nasal Spray DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    Fasedienol Nasal Spray - Fasedienol Nasal Spray DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    Fasedienol Nasal Spray - Placebo Nasal Spray DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    PH94B DRUG Phase PHASE3 Social Anxiety Disorder ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: VistaGen Therapeutics Inc.
    • CIK: 0001411685
    • Ticker Symbol: VTGN
    • Period End Date: 2025-10-27
    • Document Type: 8-K

Search

News categories